论文部分内容阅读
目的探讨S100A9在急性髓系白血病中的表达及意义。方法采用逆转录聚合酶链反应(RT-PCR)技术和免疫印迹(Western blotting)方法,从62例急性髓系白血病和12例非恶性血液病骨髓中,检测S100A9 mRNA及蛋白表达情况,分析S100A9在急性髓系白血病中和非恶性血液病表达差异及临床关系。结果急性髓系白血病组S100A9的mRNA及蛋白表达均低于非恶性血液病组(P<0.05),并且S100A9在治愈的AML中表达升高(P<0.05)。结论 S100A9在急性髓系白血病中表达降低,S100A9表达水平可能是急性髓系白血病进展判断的重要标志物。
Objective To investigate the expression and significance of S100A9 in acute myeloid leukemia. Methods The expression of S100A9 mRNA and protein in 62 cases of acute myeloid leukemia and 12 cases of non-hematologic malignancies were detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. The expression of S100A9 In acute myeloid leukemia and non-malignant hematological differences in the expression and clinical relationship. Results The mRNA and protein expression of S100A9 in acute myeloid leukemia group were lower than those in non - hematologic malignant group (P <0.05), and the expression of S100A9 in the cured AML was increased (P <0.05). Conclusions The expression of S100A9 is decreased in acute myeloid leukemia and the expression of S100A9 may be an important marker for the judgment of the progress of acute myeloid leukemia.